OpiCa1 Modulates Cardiomyocyte Viability Through PI3K/Akt Inhibition with Minimal Systemic Impact Beyond RyR Targeting
Toxins · 2025
DOI: 10.3390/toxins17110550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Xiaofen Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian…. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Proto-Oncogene Proteins c-akt, Ryanodine Receptor Calcium Release Channel, Calcium-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liang Xiao, Mei Wang, National Key Research and Development Programme of China.
Abstract (Originalsprache)
Calcins represent a class of novel peptide ligands for ryanodine receptors (RyRs), demonstrating therapeutic potential against Ca2+ dysregulation-related cardiac diseases. Nevertheless, their biological effects beyond RyR modulation and underlying mechanisms remain unexplored. This study employed Opicalcin1 (OpiCa1), the most bioactive calcin member, revealing that while it reduced cytosolic Ca2+ in H9c2 cardiomyocytes, it concurrently diminished cell viability and promoted apoptosis. Transcriptomics and Western blot analyses identified suppression of the negatively regulatory PI3K/Akt pathway as the mechanistic basis. In acute/chronic in vivo studies, high-dose OpiCa1 (≥50 mg/kg i.v.) exhibited minimal impact on body weight, histopathology, and organ indices, while accompanied with subtle alterations in serum indicators, including slight elevations in AST, ALT, and LDH, alongside mild reductions in CK-MB and TBIL-Z. These findings unveil OpiCa1’s modulation on cardiomyocyte viability through PI3K/Akt inhibition with minimal systemic impact, providing new insights into non-RyR-mediated actions of calcins and critical toxicological support for developing calcin-based therapies targeting Ca2+-dysregulated cardiac pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, School of Pharmacy, Xinjia…
- Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
- Key Laboratory of Biological Defense Ministry of Education, Second Military Medical University, Shanghai 200433, China.
- Shanghai Key Laboratory of Medical Bioprotection, Second Military Medical University, Shanghai 200433, China.
- College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming 650500, China.
- College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.
ORCID-Profile: Xiao Peng, Héctor H Valdivia
Förderung
- Liang Xiao
- Mei Wang
- National Key Research and Development Programme of China
- Higher Education Research Programme
Zitieren
APA
Ma, X., Hua, X., Peng, X., Yang, Z., Wang, Y., Zhang, Q., Wang, L., Wang, S., Valdivia, H. H., Xiao, L., & Wang, M. (2025). OpiCa1 Modulates Cardiomyocyte Viability Through PI3K/Akt Inhibition with Minimal Systemic Impact Beyond RyR Targeting. Toxins. https://doi.org/10.3390/toxins17110550
Vancouver
Ma X, Hua X, Peng X, Yang Z, Wang Y, Zhang Q, et al. OpiCa1 Modulates Cardiomyocyte Viability Through PI3K/Akt Inhibition with Minimal Systemic Impact Beyond RyR Targeting. Toxins. 2025. doi:10.3390/toxins17110550
BibTeX
@article{Ma2025,
author = {Ma, Xiaofen and Hua, Xiaoyu and Peng, Xiao and Yang, Zhixiao and Wang, Yi and Zhang, Qian and Wang, Lianbo and Wang, Shumin and Valdivia, Héctor H and Xiao, Liang and Wang, Mei},
title = {OpiCa1 Modulates Cardiomyocyte Viability Through PI3K/Akt Inhibition with Minimal Systemic Impact Beyond RyR Targeting},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17110550}
}
EUVIMED